control. **Methods:** Study subjects were adults with controlled hypertension at baseline based on two consecutive visits with normal BP readings (<140/90 mmHg or <130/80 mmHg for those with diabetes) at Medical Group A (MG-A; N = 12,766) and Medical Group B (MG-B; N = 9,768). We classified HT recidivism after follow-up for 4-16 months after the initial BP measures using the mean of the last two BP readings for each patient. **Results:** At baseline, the proportion of adults with HT who were at BP goals was 55% at MG-A, and 66% at MG-B. HT recidivism occurred in 19% of subjects with baseline controlled HT (based on two consecutive baseline visits) at MG-A and 13% of subjects at MG-B. At MG-A, men ($P = .008$) and those with higher BMI ($P < .001$) were more likely to have HT recidivism. At MG-B, those who were younger ($P < .001$) and with higher BMI ($P < .001$) were more likely to have BP recidivism. At both MGs, DBP was more likely to rise to uncontrolled levels in those age 50 or under compared to older age groups, while SBP was more likely to rise to uncontrolled levels in those age 65 or older compared to younger age groups. **Conclusions:** HT recidivism occurred in 13% to 19% of patients with previously controlled HT over a mean of 14 months of follow-up time. In medical groups with relatively high levels of baseline HT control, HT recidivism represents a brake on efforts to improve overall BP control. Effective strategies to minimize HT recidivism have great potential to improve overall levels of HT control on a population basis, and could improve HT-related quality measures at the medical group and individual provider level.

Keywords: Hypertension; Blood Pressure; Recidivism
doi:10.3121/cmr.2013.1176.ps3-30

PS3-31:

Patients with Hyperuricemia and the Effect of Urate-Lowering Therapies on Renal Function in a Managed Care Organization

Nazia Rashid¹; T. Craig Cheetham¹; Fang Niu¹; Gerald Levy¹

¹Kaiser Permanente Southern California

Background/Aims: Preliminary data suggests that elevated serum uric acid levels (sUA) play a significant role in the development of renal disease. Few studies have evaluated urate-lowering therapies (ULT) in a population with hyperuracemia and the impact on development of renal disease. Our aim was to investigate whether initiation and maintenance of ULT, in patients with sUA ≥ 7.0 mg/dL, has a beneficial impact on renal function as measured by glomerular filter rate (GFR) reductions and adverse renal outcomes. **Methods:** Patients 18 years and older, with sUA ≥ 7 mg/dL and kidney disease stage 1, 2 or 3 from 01/01/2002 to 12/31/2010 were identified within Kaiser Permanente Southern California. Serum UA levels and GFR were collected at baseline and throughout follow-up for all patients. Patients on ULT were categorized into no-treatment, $\leq 70\%$ time on treatment, and $>70\%$ time on treatment during follow-up. Patients were followed until they had one of the following primary outcomes: new onset dialysis, a 30% reduction in their GFR level from baseline, receipt of a kidney transplant, or a GFR level <15 mL/min/1.72m². Baseline characteristics between the treatment groups were compared using descriptive statistics. A Cox proportional hazards model was used to estimate the hazard ratio (HR) and 95% confidence intervals (95% CI) associated with ULT treatment controlling for patient characteristics. **Results:** A total of 33,745 patients were identified (n = 21,481 no-treatment, n = 9,136 $\leq 70\%$ time on treatment, n = 3,128 $>70\%$ time on treatment). Overall, 3,592 patients reached a study endpoint; 2,114 patients in the no-treatment, 1,109 in the $\leq 70\%$ treatment and 369 in the $>70\%$ treatment group. Controlling for demographics and co-morbid conditions, treatment for $>70\%$ of the time was associated with a 20% reduction in events (HR = 0.8; 95% CI 0.71–0.90). Factors associated with high risk of events included age, female gender, renal disease, congestive heart failure, and diabetes. **Conclusions:** Our findings suggest that ULT may preserve renal function, and prevent or delay renal outcomes such as reductions in GFR and time to dialysis.

Keywords: Urate Lowering Therapy; Renal Outcomes
doi:10.3121/cmr.2013.1176.ps3-31

PS3-32:

Patients with Co-Occurring Hypertension, Obesity, and Depression: Diagnosis vs. Treatment, and Is Treatment of One Condition Associated with Changes in Other Conditions?

Ming Tai-Seale¹; Caroline Wilson¹; Jun Ma¹; Harold Luft¹

¹Palo Alto Medical Foundation for Healthcare, Research and Education

Background/Aims: Hypertension (HTN), overweight and/or obesity (OVRWT), and depression (DEP) frequently co-occur. Research on co-occurring chronic conditions often relies on Medicare claims data, and is subject to biases from age limits and reliance on claims-based diagnoses. We use electronic health record (EHR) data from a multispecialty practice to study the occurrence of these conditions among all adults. We assess the probability that previously untreated patients with high blood pressure (BP) receive a diagnosis and subsequently are treated with drugs, and the impact of such treatment on both the BP and body mass index (BMI) of people who also have OVRWT and/or DEP. **Methods:** EHR data for 2002-2010 were used to examine BP and BMI trajectories among adults with HTN, OVRWT, or DEP and to examine the impact of prescriptions for HTN and DEP on trends in BP and BMI, controlling for patient characteristics. We used propensity score stratification to address treatment selection bias. **Results:** Most (71%; 23,806/33,326) people with any of these 3 conditions were aged <65 . About 32% (21,166/66,552) of those with high BP were neither diagnosed nor treated for HTN. Only 53% (14,254/27,016) of obese patients had a weight-related diagnosis. Recorded depression was associated with increases over time in BP (coeff = .09, $P < .01$) and BMI (coeff = .06, $P < .01$), but hypertension was associated with slower increases in BMI (coeff = -.08, $P < .01$). With propensity score stratification, growth curve modeling revealed antihypertensive treatment to be associated with declines in both BP and BMI. Depression medications were not significantly associated with BP or BMI changes. **Conclusions:** Less than two-thirds of the patients with elevated BPs were diagnosed as having HTN. The favorable impact of HTN treatment on BMI, as well as on BP, suggests addressing missed opportunities for treatment can potentially lead to better outcomes for patients with both problems.

Keywords: Multiple Chronic Conditions; Hypertension; Obesity
doi:10.3121/cmr.2013.1176.ps3-32

PS3-34:

Does Reporting of Estimated Glomerular Filtration Rates Affect Clinician Behavior?

Micah Thorp¹; David Smith¹; Eric Johnson¹; Nancy Perrin¹; Jessica Weiss²; Suma Vupputuri³; Amanda Petrik¹; Xiuhai Yang¹

¹Kaiser Permanente Northwest; ²Oregon Health and Sciences University; ³Kaiser Permanente Colorado

Background/Aims: The National Kidney Disease Education Project and other groups have recommended automated calculation and reporting of estimated glomerular filtration (eGFR) rates among all patients who have a serum creatinine measured. Few studies have assessed whether clinical practice patterns have changed in response to this new initiative. We conducted a time series analysis assessing the rate of nephrology referrals, visits and follow up laboratory testing before and after automated reporting was implemented. **Methods:** We conducted a retrospective cohort study of patients who had incident eGFR levels <60 measured before and after implementation of eGFR reporting at Kaiser Permanente Northwest (KPNW). We compared rates of subsequent evidence of clinical recognition including nephrology referral, repeat serum creatinine and proteinuria testing before and after implementation of eGFR reporting. Logistic models were used to compare change in clinical recognition rates controlling for baseline trends, and determine if the change in rates is related to clinician characteristics. **Results:** We found 21,612 patients who had an eGFR <60 , had been members for 2 years, were 18 years or older, and did not have a diagnosis of CKD. The number of referrals increased after the eGFR by 1.3 referrals per month ($P = .05$). However, the trend in monthly referral slowed after eGFR by .59 per month in comparison to the baseline trend ($P = .02$). Differences in the change in likelihood of referral after eGFR were found for age ($P = .01$), amount of FTE ($P = .04$), and type of practice ($P = .01$). Slope changes